Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A
Abstract The in vitro antibacterial effect of a synthetic new peptide NJP9-A originated from natural marine invertebrates and its cytotoxicity, selectivity and one possible mechanism of action on human leukemia cells were investigated. NJP9-A showed significant bacteriostasis against Staphylococcus aureus (including methicillin-resistant S. aureus), and had a very low hemolysis efficiency on the human red blood cells. NJP9-A selectively bound to and inhibited the proliferation of leukemia cells, but had almost no inhibitory effect on the proliferation of HEK293 and HUVEC cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect may involve changing the expression of PIK3R1 (PI3K p85 regulatory subunit 1), and the corresponding PI3K signal transduction pathway. NJP9-A inhibits Gram-positive bacteria and is cytotoxic to leukemia cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect is still unclear, but it may be related to the alteration of PIK3R1 expression..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
---|---|
Enthalten in: |
Letters in peptide science - 27(2021), 4 vom: 02. Juli, Seite 2199-2207 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ren, Kai [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Gram-positive bacteria |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2021 |
---|
doi: |
10.1007/s10989-021-10246-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR045476977 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR045476977 | ||
003 | DE-627 | ||
005 | 20230519153246.0 | ||
007 | cr uuu---uuuuu | ||
008 | 211104s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10989-021-10246-4 |2 doi | |
035 | |a (DE-627)SPR045476977 | ||
035 | |a (SPR)s10989-021-10246-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |q ASE |
084 | |a 35.76 |2 bkl | ||
100 | 1 | |a Ren, Kai |e verfasserin |4 aut | |
245 | 1 | 0 | |a Preliminary Study on the Antibacterial and Cytotoxic Effects of the Synthetic New Peptide NJP9-A |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2021 | ||
520 | |a Abstract The in vitro antibacterial effect of a synthetic new peptide NJP9-A originated from natural marine invertebrates and its cytotoxicity, selectivity and one possible mechanism of action on human leukemia cells were investigated. NJP9-A showed significant bacteriostasis against Staphylococcus aureus (including methicillin-resistant S. aureus), and had a very low hemolysis efficiency on the human red blood cells. NJP9-A selectively bound to and inhibited the proliferation of leukemia cells, but had almost no inhibitory effect on the proliferation of HEK293 and HUVEC cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect may involve changing the expression of PIK3R1 (PI3K p85 regulatory subunit 1), and the corresponding PI3K signal transduction pathway. NJP9-A inhibits Gram-positive bacteria and is cytotoxic to leukemia cells. The underlying mechanism of NJP9-A’s anti-leukemia cell effect is still unclear, but it may be related to the alteration of PIK3R1 expression. | ||
650 | 4 | |a Leukemia cells |7 (dpeaa)DE-He213 | |
650 | 4 | |a Gram-positive bacteria |7 (dpeaa)DE-He213 | |
650 | 4 | |a Synthetic peptide NJP9-A |7 (dpeaa)DE-He213 | |
650 | 4 | |a Selectivity |7 (dpeaa)DE-He213 | |
700 | 1 | |a Chi, Xiumei |e verfasserin |4 aut | |
700 | 1 | |a Wu, Tiange |e verfasserin |4 aut | |
700 | 1 | |a Kan, Mujie |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jiankai |e verfasserin |4 aut | |
700 | 1 | |a Cui, Jiayue |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Letters in peptide science |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1994 |g 27(2021), 4 vom: 02. Juli, Seite 2199-2207 |w (DE-627)SPR015385973 |w (DE-600)2007589-3 |x 1573-496X |7 nnns |
773 | 1 | 8 | |g volume:27 |g year:2021 |g number:4 |g day:02 |g month:07 |g pages:2199-2207 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10989-021-10246-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 35.76 |q ASE |
951 | |a AR | ||
952 | |d 27 |j 2021 |e 4 |b 02 |c 07 |h 2199-2207 |